Disclosed herein is the use of a compound which is [2-({ 4-[(dimethylamino)iminomethyl]phenyl} carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide and a P2Y12 receptor antagonist in the manufacture of a medicament for treating a condition in a mammal characterized by undesired thrombosis, wherein the medicament is formulated for separate, sequential or simultaneous administration of the compound and the P2Y12 receptor antagonist, and wherein the P2Y12 receptor antagonist is selected from the group consisting of cangrelor, ticagrelor, clopidogrel, ticlopidine and prasugrel. Optionally comprising a third therapeutic agent selected from the group consisting of an antiplatelet agent, an anti-coagulant, a thrombin inhibitor, a thrombolytic agent, an antiarrhythmic agent, a blood pressure lowering agent, a cholesterol and a triglyceride lowering agent.
